Involved-field irradiation concurrently combined with XXXX / @entity1487 for inoperable @entity418 on basis of (18)FDG-PET scans: A phase II study.

@entity1 @entity5 @entity957 @entity1487 @entity418 @entity3 @entity1814
PURPOSE: A prospective study was performed on chemoradiotherapy (CRT) for @entity418 using involved-field radiation therapy (IFRT) based on 18-fluorodeoxyglucose positron-emission tomography. The goal of this phase II study was to evaluate the efficacy of the IFRT procedure in newly diagnosed @entity418 . @entity1 AND METHODS: Eligible @entity1 were adults with newly diagnosed untreated, inoperable @entity418 in stages I-IV with lymph node @entity3 . @entity1 received @entity1814 80mg/m(2) per day on day 1, @entity1487 800mg/m(2) on days 1-4 intravenously repeated every 28days for 2-4 cycles, and combined IFRT. Elective nodal irradiation was not performed. Irradiation was applied only to the @entity5 and positive lymph nodes. RESULTS: From September 2009 to July 2012, of the 63 @entity1 enrolled, 58 were evaluable for response. The primary end point of isolated out-of-field loco-regional nodal recurrence was seen in only two @entity1 . The expectant rate was assumed to be less than 5%. The threshold value was set as 10% to calculate the number of registrations. Progression-free and overall survival rates at 36months were 47.7% and 51.1%, respectively. The median progression-free survival was 34.6months, and overall survival was 38.4months. Salvage surgery was tried for 11 @entity1 (17.5%) due to residual or recurrent disease. CONCLUSION: The primary end point of the trial was demonstrated, indicating the efficacy of IFRT in the treatment of inoperable @entity418 mostly of @entity957 .
